Alzheimer’s disease
43 results
1 - 43
18F‐FDG PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)- 11C‐PIB‐PET for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)
- 18F PET with florbetapir for the early diagnosis of Alzheimer’s disease dementia and other dementias in people with mild cognitive impairment (MCI)
- CSF tau and the CSF tau/ABeta ratio for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)
- 18F PET with flutemetamol for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)
- 18F PET with florbetaben for the early diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)
- Latrepirdine for Alzheimer's disease
- Aspirin, steroidal and non‐steroidal anti‐inflammatory drugs for the treatment of Alzheimer's disease
- Withdrawal or continuation of cholinesterase inhibitors or memantine or both, in people with dementia
- Plasma and cerebrospinal fluid amyloid beta for the diagnosis of Alzheimer's disease dementia and other dementias in people with mild cognitive impairment (MCI)
- The Rowland Universal Dementia Assessment Scale (RUDAS) for the detection of dementia in a variety of healthcare settings
- Cognitive training and cognitive rehabilitation for mild to moderate Alzheimer's disease and vascular dementia: Cochrane systematic review
- Souvenaid for Alzheimer's disease
- Antipsychotics for agitation and psychosis in people with Alzheimer's disease and vascular dementia
- Cognitive training for people with mild to moderate dementia
- Pharmacist services for non-hospitalised patients: Cochrane systematic review
- Cholinergic medication for antipsychotic‐induced tardive dyskinesia
- Pharmacological interventions for apathy in Alzheimer's disease
- Regional Cerebral Blood Flow Single Photon Emission Computed Tomography for detection of Frontotemporal dementia in people with suspected dementia
- Mini‐Mental State Examination (MMSE) for the early detection of dementia in people with mild cognitive impairment (MCI)
- Plasma and cerebrospinal fluid ABeta42 for the differential diagnosis of Alzheimer's disease dementia in participants diagnosed with any dementia subtype in a specialist care setting
- Antithrombotic therapy to prevent cognitive decline in people with small vessel disease on neuroimaging but without dementia
- Cognitive rehabilitation for people with mild to moderate dementia
- Dopamine transporter imaging for the diagnosis of dementia with Lewy bodies
- Vitamin and mineral supplementation for preventing dementia or delaying cognitive decline in people with mild cognitive impairment
- Cognitive stimulation to improve cognitive functioning in people with dementia